Futura Medical plc (LSE:FUM) is in focus as investors assess recent company developments, execution and the next set of measurable business milestones.
Optima Health plc (LSE:OPT) is in focus as investors assess recent company developments, execution and the next set of measurable business milestones.
hVIVO runs human challenge studies, in which volunteers are deliberately exposed to a pathogen under controlled conditions to test vaccines and antivirals. It operates from London and also offers laboratory, early-phase clinical and patient recruitment services. The group now trades under a single hVIVO …
ImmuPharma is a specialist drug discovery and development company. Its lead asset is P140, also known as Lupuzor or forigerimod, a peptide being developed for autoimmune and inflammatory diseases. Kapiglucagon is a wholly owned glucagon prodrug designed to allow stable liquid formulations, mainly for …
Thalia Therapeutics PLC (LSE:THAT) is being assessed against its exposure to life-sciences investment and therapeutic development.
The stock sits within the wider London Stock Exchange AIM market and the FTSE AIM All-Share universe. For smaller listed companies, investor attention can shift quickly when a company reports a financing, operating update, project milestone or strategic decision. The index context is useful …
Proteome Sciences plc (LSE:PRM) is an AIM-traded company whose investment case centres on proteomics services and biomarker research. The current market discussion is shaped by demand for outsourced proteomics and diagnostics research. The central question for investors is whether strategic progress can translate into …
Abingdon Health (LSE:ABDX) is in focus following its final results announcement on 13 October 2026. The development gives investors a fresh point at which to reassess the company’s strategy, execution priorities and the evidence needed to judge whether the announcement can create lasting value. …
Aptamer Group (LSE:APTA) is in focus following its full-year results for the 12 months to 30 june 2026 announcement on 13 October 2026. The development gives investors a fresh point at which to reassess the company’s strategy, execution priorities and the evidence needed to …
Emv Capital (LSE:EMVC) is in focus following its glycotest intellectual-property licensing announcement announcement on 13 October 2026. The development gives investors a fresh point at which to reassess the company’s strategy, execution priorities and the evidence needed to judge whether the announcement can create …